WALVAX(SZ:300142) Xin Lang Cai Jing·2026-01-21 02:37Core Viewpoint - Watson Bio's stock has shown fluctuations in price and trading volume, with a notable increase in share price since the beginning of the year, despite recent declines in the short term [1]. Financial Performance - For the period from January to September 2025, Watson Bio reported a revenue of 1.719 billion yuan, representing a year-on-year decrease of 19.73% [2]. - The net profit attributable to shareholders for the same period was 163 million yuan, down 36.24% year-on-year [2]. Shareholder Information - As of September 30, 2025, the number of shareholders for Watson Bio was 114,000, a decrease of 2.75% from the previous period [2]. - The average number of circulating shares per shareholder increased by 2.83% to 13,643 shares [2]. Dividend Distribution - Since its A-share listing, Watson Bio has distributed a total of 451 million yuan in dividends, with 95.96 million yuan distributed over the last three years [3]. Institutional Holdings - As of September 30, 2025, the largest circulating shareholder was E Fund's ChiNext ETF, holding 34.4714 million shares, a decrease of 5.8005 million shares from the previous period [3]. - Other notable institutional shareholders include Southern CSI 500 ETF and China Merchants National Bio-Medical Index A, both of which also saw reductions in their holdings [3].